japanes
woman
acut
myeloid
leukemia
receiv
allogen
bone
marrow
transplant
bmt
allel
unrel
donor
first
remiss
phase
condit
regimen
consist
mgkg
busulfan
day
fludarabin
day
gvhd
prophylaxi
consist
tacrolimu
methotrex
rapid
engraft
observ
chimer
analysi
demonstr
whole
blood
cell
donor
deriv
day
bmt
marrow
aspir
day
reveal
blast
confirm
complet
remiss
acut
gvhd
sign
symptom
observ
day
chimer
analysi
whole
blood
cell
show
decreas
cell
concurr
chimer
analysi
demonstr
cell
cell
although
mononuclear
cell
mnc
granulocyt
donor
deriv
base
find
tacrolimu
taper
discontinu
howev
neither
recoveri
cell
gvhd
symptom
observ
approxim
month
discontinu
immunosuppress
dli
dose
recipi
bodi
weight
perform
donor
day
day
dli
patient
complain
spontan
itchi
dri
skin
erupt
face
suspect
gvhd
skin
erupt
continu
day
without
progress
improv
without
treatment
day
day
patient
complain
mild
dyspnea
fever
gradual
worsen
day
chest
radiographi
day
show
diffus
shadow
lower
lung
field
chest
comput
tomographi
ct
day
reveal
diffus
bilater
ground
glass
opac
reticular
appear
predominantli
lower
lung
field
fig
pulmonari
function
test
show
declin
forc
vital
capac
l
l
well
percentag
vital
capac
almost
chang
forc
expiratori
volum
second
indic
restrict
lung
dysfunct
day
fiber
optic
bronchoscopi
bronchoalveolar
lavag
perform
due
small
sampl
histolog
find
transbronchi
lung
biopsi
show
trivial
alveolar
edema
without
evid
leukemia
infiltr
specimen
includ
bronchiol
differenti
diagnosi
copboop
identif
bo
chronic
gvhd
analysi
balf
show
total
cell
count
cellsml
differenti
cell
count
macrophag
lymphocyt
granulocyt
lymphocyt
cell
ratio
bacteri
mycobacteri
fungal
cultur
balf
neg
cytomegaloviru
antigenemia
test
also
neg
balf
also
shown
neg
influenza
includ
subtyp
influenza
b
rsv
b
hmpv
piv
coronaviru
rhinovirusenteroviru
adenoviru
bocaviru
respiratori
viral
panel
fast
assay
luminex
xtag
luminex
diagnost
toronto
canada
base
find
diagnos
nipc
induc
dli
day
prednisolon
psl
administ
dose
mgkgday
led
rapid
clinic
improv
ct
day
initi
psl
treatment
show
remark
improv
abnorm
shadow
fig
psl
dose
taper
discontinu
month
onset
without
recurr
nipc
blood
sampl
cytokin
determin
collect
patient
psl
treatment
well
four
weekli
time
point
initi
psl
treatment
written
inform
consent
cell
balf
also
collect
phenotyp
chimer
analysi
balf
serum
cell
separ
immedi
store
assay
perform
clarifi
whether
nipc
dli
induc
infus
donor
cell
chimer
peripher
blood
mononuclear
cell
pbmnc
balf
assess
polymeras
chain
reaction
analysi
short
tandem
repeat
loci
use
cell
line
identif
system
cell
id
promega
corp
madison
wi
accord
manufactur
instruct
cytokin
sera
quantit
use
suspens
array
system
pro
human
cytokin
group
panel
laboratori
inc
hercul
ca
panel
includ
cytokin
chemokin
interleukin
il
eotaxin
fibroblast
growth
factor
fgf
factor
factor
interferon
ifn
induc
macrophag
inflammatori
protein
mip
growth
factor
pdgf
rant
tumor
necrosi
factor
tnf
vascular
endotheli
growth
factor
vegf
accord
manufactur
shown
tabl
approxim
mnc
mnc
donor
origin
balf
suggest
chimer
predominantli
patient
cell
balf
chimer
approxim
compar
peripher
blood
patient
serum
analysi
reveal
signific
elev
nine
cytokin
chemokin
vegf
onset
nipc
declin
soon
initi
psl
treatment
fig
kinet
psl
treatment
shown
fig
gray
shadow
indic
rang
normal
concentr
calcul
median
use
five
healthi
donor
vegf
level
significantli
differ
normal
rang
healthi
control
detect
limit
concentr
cytokin
chemokin
also
measur
chang
clinic
cours
psl
treatment
figur
shown
sinc
first
report
dli
treatment
cml
publish
kolb
colleagu
numer
clinic
trial
dli
variou
hematolog
malign
although
efficaci
dli
depend
diseas
type
statu
dli
shown
direct
effect
infus
alloreact
donor
cell
hand
dli
may
induc
sever
advers
effect
includ
sever
gvhd
patient
complain
dyspnea
fever
suspect
complic
pulmonari
gvhd
alloreact
donor
cell
recogn
alloantigen
previou
studi
suggest
infus
lymphocyt
lead
lung
injuri
murin
gvhd
model
although
lung
gener
consid
classic
target
organ
acut
clarifi
whether
nipc
patient
pulmonari
gvhd
induc
infus
donor
lymphocyt
perform
chimer
analysi
cell
balf
demonstr
cell
recruit
patient
lung
exclus
deriv
donor
cell
result
suggest
pathogenesi
nipc
due
attack
cytotox
cell
directli
recogn
patient
pulmonari
tissu
migrat
patient
cell
activ
dli
analysi
cytokin
profil
reveal
kinet
inflammatori
mediat
proinflammatori
cytokin
chemokin
serum
elev
onset
patient
pulmonari
symptom
decreas
treatment
psl
phenomenon
previous
report
ip
occur
earli
period
transplant
import
chemokin
ip
also
report
murin
ip
frequent
fatal
complic
incid
median
onset
time
second
third
week
clinic
outcom
patient
ip
poor
mortal
rang
median
time
diagnosi
death
short
day
risk
factor
classic
ip
includ
condit
total
bodi
irradi
acut
base
previou
find
thought
potenti
etiolog
ip
includ
direct
toxic
effect
condit
regimen
releas
inflammatori
cytokin
cytokin
profil
present
case
suggest
nipc
result
system
immun
respons
stimul
dli
conclus
elev
cytokin
chemokin
measur
present
case
may
play
import
role
pathogenesi
nipc
dli
studi
cytokin
chemokin
profil
dli
number
patient
may
clarifi
pathophysiolog
nipc
author
disclos
conflict
interest
